Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Toi

Showing results (51-60 of 222) with videos related to

Pageof 23
Sort By:
Breast Cancer Research and Treatment|January 1, 1994
Role of epidermal growth factor receptor expression in primary breast cancer: results of a biochemical study and an immunocytochemical studyM Toi, T Tominaga, A Osaki, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|March 1, 1988
[Effects of high-dose medroxyprogesterone acetate in advanced breast cancer, with special reference to prior endocrine therapy and hormone receptors]Y Nomura, H Tashiro, K Hisamatsu, et al.
Oncology Reports|May 19, 2011
The increase of apoptosis and the decrease of proliferation by angiogenesis inhibitor in rat mammary tumorsS Saji, M Toi, Y Yamamoto, et al.
Oncology Reports|May 25, 2011
Inhibition of vascular endothelial growth-factor induced cell-growth by an angiogenesis inhibitor agm-1470 in capillary endothelial-cellsM Toi, T Takayanagi, R Souma, et al.
Lung Cancer (Amsterdam, Netherlands)|November 1, 1996
Clinical correlates of bombesin-like peptide receptor subtype expression in human lung cancer cellsM Toi-Scott, C L Jones, M A Kane
Histopathology|October 12, 2007
Diagnostic pitfall of D2-40 in adenomatosid tumourN Kuroda, M Toi, M Hiroi, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|February 1, 1995
Sweat gland carcinoma in a human immunodeficiency virus-infected patientM Toi, L Kauffman, L Peterson, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|April 1, 1997
[The feasibility of CEF (cyclophosphamide, epirubicin, 5-FU) regimen in the adjuvant setting of primary breast cancer]S Honda, M Toi, S Shimizu, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|December 10, 1999
[Docetaxel as a single agent in cases of advanced/recurrent breast cancer previously treated with anthracycline]S Nagai, M Toi, K Kuroi, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|March 2, 2006
Current directions for COX-2 inhibition in breast cancerL W C Chow, W T Y Loo, M Toi
Pageof 23

Showing results (51-60 of 222) with videos related to

Sort By:
Pageof 23
Breast Cancer Research and Treatment|January 1, 1994
Role of epidermal growth factor receptor expression in primary breast cancer: results of a biochemical study and an immunocytochemical studyM Toi, T Tominaga, A Osaki, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|March 1, 1988
[Effects of high-dose medroxyprogesterone acetate in advanced breast cancer, with special reference to prior endocrine therapy and hormone receptors]Y Nomura, H Tashiro, K Hisamatsu, et al.
Oncology Reports|May 19, 2011
The increase of apoptosis and the decrease of proliferation by angiogenesis inhibitor in rat mammary tumorsS Saji, M Toi, Y Yamamoto, et al.
Oncology Reports|May 25, 2011
Inhibition of vascular endothelial growth-factor induced cell-growth by an angiogenesis inhibitor agm-1470 in capillary endothelial-cellsM Toi, T Takayanagi, R Souma, et al.
Lung Cancer (Amsterdam, Netherlands)|November 1, 1996
Clinical correlates of bombesin-like peptide receptor subtype expression in human lung cancer cellsM Toi-Scott, C L Jones, M A Kane
Histopathology|October 12, 2007
Diagnostic pitfall of D2-40 in adenomatosid tumourN Kuroda, M Toi, M Hiroi, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|February 1, 1995
Sweat gland carcinoma in a human immunodeficiency virus-infected patientM Toi, L Kauffman, L Peterson, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|April 1, 1997
[The feasibility of CEF (cyclophosphamide, epirubicin, 5-FU) regimen in the adjuvant setting of primary breast cancer]S Honda, M Toi, S Shimizu, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|December 10, 1999
[Docetaxel as a single agent in cases of advanced/recurrent breast cancer previously treated with anthracycline]S Nagai, M Toi, K Kuroi, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|March 2, 2006
Current directions for COX-2 inhibition in breast cancerL W C Chow, W T Y Loo, M Toi
Pageof 23